

# Ravi A Madan

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/51250/ravi-a-madan-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

155  
papers

4,806  
citations

38  
h-index

65  
g-index

167  
ext. papers

5,822  
ext. citations

6.4  
avg, IF

5.49  
L-index

#	Paper	IF	Citations
155	Immunotherapy for Metastatic Prostate Cancer <b>2022</b> , 131-146		
154	A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1).. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2022</b> ,	6.2	2
153	Lutetium-177-PSMA-617: A Vision of the Future.. <i>Cancer Biology and Therapy</i> , <b>2022</b> , 23, 186-190	4.6	1
152	Assessment of Aortoiliac Atherosclerotic Plaque on CT in Prostate Cancer Patients Undergoing Treatment.. <i>Tomography</i> , <b>2022</b> , 8, 607-616	3.1	
151	Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer <b>2021</b> , 9,		2
150	Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC) <b>2021</b> , 9,		10
149	Disparities in Cancer Care and the Asian American Population. <i>Oncologist</i> , <b>2021</b> , 26, 453-460	5.7	4
148	Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy. <i>European Urology</i> , <b>2021</b> , 80, 746-757	10.2	14
147	Protein kinase inhibitors for the treatment of prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , <b>2021</b> , 22, 1889-1899	4	2
146	Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic Response. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 429-437	12.9	5
145	Cabozantinib plus docetaxel and prednisone in metastatic castration-resistant prostate cancer. <i>BJU International</i> , <b>2021</b> , 127, 435-444	5.6	3
144	Deep Learning Based Staging of Bone Lesions From Computed Tomography Scans. <i>IEEE Access</i> , <b>2021</b> , 9, 87531-87542	3.5	3
143	Randomized, Double-Blind, Placebo-Controlled Phase II Study of Yeast-Brachyury Vaccine (GI-6301) in Combination with Standard-of-Care Radiotherapy in Locally Advanced, Unresectable Chordoma. <i>Oncologist</i> , <b>2021</b> , 26, e847-e858	5.7	9
142	Behind the IL-8 ball in prostate cancer.. <i>Nature Cancer</i> , <b>2021</b> , 2, 775-776	15.4	1
141	Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single-Dose Administration Under Fasting Conditions in Prostate Cancer. <i>Oncologist</i> , <b>2021</b> , 26, 729-e1493	5.7	1
140	Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer <b>2021</b> , 9,		3
139	The World of Clinical Trial Development Post COVID-19: Lessons Learned from a Global Pandemic. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 4198-4200	12.9	7

138	Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T. <i>Journal of the National Cancer Institute</i> , <b>2020</b> , 112, 562-573	9.7	21
137	The immunotherapy revolution in genitourinary malignancies. <i>Immunotherapy</i> , <b>2020</b> , 12, 819-831	3.8	7
136	Evaluating Biochemically Recurrent Prostate Cancer: Histologic Validation of F-DCFPyL PET/CT with Comparison to Multiparametric MRI. <i>Radiology</i> , <b>2020</b> , 296, 564-572	20.5	9
135	A case report of multiple primary prostate tumors with differential drug sensitivity. <i>Nature Communications</i> , <b>2020</b> , 11, 837	17.4	10
134	Phase I Trial of a Modified Vaccinia Ankara Priming Vaccine Followed by a Fowlpox Virus Boosting Vaccine Modified to Express Brachyury and Costimulatory Molecules in Advanced Solid Tumors. <i>Oncologist</i> , <b>2020</b> , 25, 560-e1006	5.7	10
133	Endocrine-Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management. <i>Oncologist</i> , <b>2020</b> , 25, 290-300	5.7	28
132	Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer <b>2020</b> , 8,		21
131	A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)-Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer. <i>Oncologist</i> , <b>2020</b> , 25, 479-e899	5.7	23
130	Measurement of NLG207 (formerly CRLX101) nanoparticle-bound and released camptothecin in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2020</b> , 181, 113073	3.5	6
129	Novel immunotherapy combinations for genitourinary cancers. <i>Expert Opinion on Biological Therapy</i> , <b>2020</b> , 20, 253-262	5.4	9
128	The Potential Role for Immunotherapy in Biochemically Recurrent Prostate Cancer. <i>Urologic Clinics of North America</i> , <b>2020</b> , 47, 457-467	2.9	2
127	A Case Report of Sequential Use of a Yeast-CEA Therapeutic Cancer Vaccine and Anti-PD-L1 Inhibitor in Metastatic Medullary Thyroid Cancer. <i>Frontiers in Endocrinology</i> , <b>2020</b> , 11, 490	5.7	5
126	Exploiting defects in homologous recombination repair for metastatic, castration-resistant prostate cancer. <i>Cancer Biology and Therapy</i> , <b>2020</b> , 21, 884-887	4.6	0
125	Population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of NLG207 in adults with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2020</b> , 86, 475-486	3.5	3
124	Bintrafusp alfa, a bifunctional fusion protein targeting TGF- $\beta$ and PD-L1, in patients with human papillomavirus-associated malignancies <b>2020</b> , 8,		21
123	Ferumoxitol-Enhanced MR Lymphography for Detection of Metastatic Lymph Nodes in Genitourinary Malignancies: A Prospective Study. <i>American Journal of Roentgenology</i> , <b>2020</b> , 214, 105-113	5.4	8
122	Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors <b>2019</b> , 7, 240		85
121	A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 4933-4944	12.9	27

120	A Case of Anti-PD-L1-associated Remitting Seronegative Symmetric Synovitis With Pitting Edema. <i>Clinical Genitourinary Cancer</i> , <b>2019</b> , 17, e549-e552	3.3	3
119	First-in-Human Phase I Trial of a Tumor-Targeted Cytokine (NHS-IL12) in Subjects with Metastatic Solid Tumors. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 99-109	12.9	71
118	A population pharmacokinetic analysis of the oral CYP17 lyase and androgen receptor inhibitor seviteronel in patients with advanced/metastatic castration-resistant prostate cancer or breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2019</b> , 84, 759-770	3.5	2
117	Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma <b>2019</b> , 7, 269		43
116	Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy. <i>Oncologist</i> , <b>2019</b> , 24, 1259-1269	5.7	67
115	Phase I/II Trial of Vandetanib and Bortezomib in Adults with Locally Advanced or Metastatic Medullary Thyroid Cancer. <i>Oncologist</i> , <b>2019</b> , 24, 16-e14	5.7	7
114	Targeting the Tumor Microenvironment with Immunotherapy for Genitourinary Malignancies. <i>Current Treatment Options in Oncology</i> , <b>2018</b> , 19, 16	5.4	5
113	Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGF $\beta$ in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 1287-1295	12.9	195
112	A Prospective Comparison of F-Sodium Fluoride PET/CT and PSMA-Targeted F-DCFBC PET/CT in Metastatic Prostate Cancer. <i>Journal of Nuclear Medicine</i> , <b>2018</b> , 59, 1665-1671	8.9	29
111	A comparison of prostate cancer bone metastases on F-Sodium Fluoride and Prostate Specific Membrane Antigen (F-PSMA) PET/CT: Discordant uptake in the same lesion. <i>Oncotarget</i> , <b>2018</b> , 9, 37676-37688	3.3	9
110	Perspectives on the clinical development of immunotherapy in prostate cancer. <i>Asian Journal of Andrology</i> , <b>2018</b> , 20, 253-259	2.8	11
109	Expanding the use of abiraterone in prostate cancer: Is earlier always better?. <i>Cancer Biology and Therapy</i> , <b>2018</b> , 19, 97-100	4.6	
108	The Winds of Change: Emerging Therapeutics in Prostate Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2018</b> , 38, 382-390	7.1	1
107	A Randomized, Double-blind, Phase II Trial of PSA-TRICOM (PROSTVAC) in Patients with Localized Prostate Cancer: The Immunotherapy to Prevent Progression on Active Surveillance Study. <i>European Urology Focus</i> , <b>2018</b> , 4, 636-638	5.1	8
106	Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations <b>2018</b> , 6, 141		132
105	A Phase II Clinical Trial of TRC105 (Anti-Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> , 15, 77-85	3.3	33
104	Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody <b>2017</b> , 5, 20		57
103	Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, 587-598	21.7	194

102	Docetaxel extravasation: Pathologic correlation and treatment with intralesional steroids. <i>JAAD Case Reports</i> , <b>2017</b> , 3, 322-325	1.4	0
101	Combining immunotherapies for the treatment of prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2017</b> , 35, 694-700	2.8	18
100	A Phase II Multi-Center Study of Bevacizumab in Combination with Ixabepilone in Subjects with Advanced Renal Cell Carcinoma. <i>Oncologist</i> , <b>2017</b> , 22, 888-e84	5.7	2
99	Prostate cancer immunotherapy: the path forward. <i>Current Opinion in Supportive and Palliative Care</i> , <b>2017</b> , 11, 225-230	2.6	5
98	Immunotherapy of Prostate Cancer: Facts and Hopes. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 6764-6770	12.9	108
97	Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment. <i>Journal of the National Cancer Institute</i> , <b>2017</b> , 109,	9.7	104
96	Phase I Study of a Poxviral TRICOM-Based Vaccine Directed Against the Transcription Factor Brachyury. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 6833-6845	12.9	39
95	Analyses of 123 Peripheral Human Immune Cell Subsets: Defining Differences with Age and between Healthy Donors and Cancer Patients Not Detected in Analysis of Standard Immune Cell Types. <i>Journal of Circulating Biomarkers</i> , <b>2016</b> , 5, 5	3.3	34
94	Metabolic syndrome in prostate cancer: impact on risk and outcomes. <i>Future Oncology</i> , <b>2016</b> , 12, 1947-55.6	5.6	5
93	Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer. <i>BJU International</i> , <b>2016</b> , 118, 590-7	5.6	19
92	Prospective Study Evaluating Na18F PET/CT in Predicting Clinical Outcomes and Survival in Advanced Prostate Cancer. <i>Journal of Nuclear Medicine</i> , <b>2016</b> , 57, 886-92	8.9	64
91	Therapeutic vaccines for prostate cancer: recent advances and future directions. <i>Expert Review of Vaccines</i> , <b>2016</b> , 15, 907-14	5.2	5
90	Prospects for the future of prostate cancer vaccines. <i>Expert Review of Vaccines</i> , <b>2016</b> , 15, 271-4	5.2	4
89	Samarium-153-EDTMP (Quadramet <sup>®</sup> ) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial. <i>Oncotarget</i> , <b>2016</b> , 7, 69014-69023	3.3	31
88	The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells. <i>Oncotarget</i> , <b>2016</b> , 7, 37762-37772	3.3	76
87	The evolving role of immunotherapy in prostate cancer. <i>Current Opinion in Oncology</i> , <b>2016</b> , 28, 232-40	4.2	10
86	TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancer. <i>Onc Immunology</i> , <b>2016</b> , 5, e1197459	7.2	19
85	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma <b>2016</b> , 4, 92		25

84	Immunotherapy in genitourinary malignancies. <i>Current Opinion in Urology</i> , <b>2016</b> , 26, 501-7	2.8	5
83	Considerations for the combination of anticancer vaccines and immune checkpoint inhibitors. <i>Expert Opinion on Biological Therapy</i> , <b>2016</b> , 16, 895-901	5.4	15
82	Developing immunotherapy strategies in the treatment of prostate cancer. <i>Asian Journal of Urology</i> , <b>2016</b> , 3, 278-285	2.7	8
81	Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy. <i>Cancer Immunology Research</i> , <b>2016</b> , 4, 755-65	12.5	25
80	Radium-223 in prostate cancer: emitting the right signals. <i>Lancet Oncology, The</i> , <b>2016</b> , 17, 1186-7	21.7	1
79	Evaluating immune responses after sipuleucel-T therapy. <i>Cancer Biology and Therapy</i> , <b>2015</b> , 16, 1119-21	4.6	3
78	Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury. <i>Cancer Immunology Research</i> , <b>2015</b> , 3, 1248-56	12.5	89
77	Moving the goal posts in prostate cancer trials. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, 247-9	21.7	3
76	The impact of leukapheresis on immune-cell number and function in patients with advanced cancer. <i>Cancer Immunology, Immunotherapy</i> , <b>2015</b> , 64, 1429-35	7.4	2
75	Randomized phase II trial of docetaxel with or without PSA-TRICOM vaccine in patients with castrate-resistant metastatic prostate cancer: A trial of the ECOG-ACRIN cancer research group (E1809). <i>Human Vaccines and Immunotherapeutics</i> , <b>2015</b> , 11, 2469-74	4.4	22
74	Integrating Immunotherapies in Prostate Cancer. <i>Current Oncology Reports</i> , <b>2015</b> , 17, 45	6.3	3
73	A phase I study of TRC105 anti-endoglin (CD105) antibody in metastatic castration-resistant prostate cancer. <i>BJU International</i> , <b>2015</b> , 116, 546-55	5.6	45
72	Detection and Characterization of Circulating Tumour Cells from Frozen Peripheral Blood Mononuclear Cells. <i>Journal of Circulating Biomarkers</i> , <b>2015</b> , 4, 4	3.3	6
71	Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2015</b> , 1, 1087-95	13.4	58
70	Abiraterone's efficacy confirmed; time to aim higher. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, 119-21	21.7	1
69	(R)Evolutionary therapy: the potential of immunotherapy to fulfill the promise of personalized cancer treatment. <i>Journal of the National Cancer Institute</i> , <b>2015</b> , 107, 347	9.7	4
68	Beyond PSA: managing modern therapeutic options in metastatic castration-resistant prostate cancer. <i>Southern Medical Journal</i> , <b>2015</b> , 108, 224-8	0.6	11
67	The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic. <i>Oncotarget</i> , <b>2015</b> , 6, 31344-59	3.3	24

66	Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma. <i>Cancer Immunology, Immunotherapy</i> , <b>2014</b> , 63, 225-34	7.4	70
65	Therapeutic Cancer Vaccines: An Emerging Approach to Cancer Treatment. <i>Cancer Drug Discovery and Development</i> , <b>2014</b> , 553-568	0.3	
64	Identification by digital immunohistochemistry of intratumoral changes of immune infiltrates after vaccine in the absence of modifications of PBMC immune cell subsets. <i>International Journal of Cancer</i> , <b>2014</b> , 135, 862-70	7.5	4
63	Recent advances in the use of therapeutic cancer vaccines in genitourinary malignancies. <i>Expert Opinion on Biological Therapy</i> , <b>2014</b> , 14, 1769-81	5.4	3
62	Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer. <i>Cancer Immunology Research</i> , <b>2014</b> , 2, 133-41	12.5	93
61	Real-world experience with abiraterone. <i>Lancet Oncology, The</i> , <b>2014</b> , 15, 1188-90	21.7	
60	Cabozantinib-induced thyroid dysfunction: a review of two ongoing trials for metastatic bladder cancer and sarcoma. <i>Thyroid</i> , <b>2014</b> , 24, 1223-31	6.2	22
59	A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates. <i>Cancer Immunology, Immunotherapy</i> , <b>2014</b> , 63, 407-18	7.4	71
58	Exploiting synergy: immune-based combinations in the treatment of prostate cancer. <i>Frontiers in Oncology</i> , <b>2014</b> , 4, 351	5.3	12
57	Therapeutic cancer vaccines. <i>Advances in Cancer Research</i> , <b>2014</b> , 121, 67-124	5.9	49
56	Poxviral-based vaccine elicits immunologic responses in prostate cancer patients. <i>OncolImmunology</i> , <b>2014</b> , 3, e28611	7.2	10
55	Recent advances revolutionize treatment of metastatic prostate cancer. <i>Future Oncology</i> , <b>2013</b> , 9, 1133-46	3.6	15
54	Phase II study of satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer: a pharmacogenetic assessment of outcome and toxicity. <i>Clinical Genitourinary Cancer</i> , <b>2013</b> , 11, 229-37	3.3	20
53	Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer. <i>Cancer Immunology, Immunotherapy</i> , <b>2013</b> , 62, 1521-31	7.4	31
52	Ipilimumab in prostate cancer. <i>Expert Opinion on Biological Therapy</i> , <b>2013</b> , 13, 303-13	5.4	5
51	Demystifying immunotherapy in prostate cancer: understanding current and future treatment strategies. <i>Cancer Journal (Sudbury, Mass)</i> , <b>2013</b> , 19, 50-8	2.2	17
50	Effect of talactoferrin alfa on the immune system in adults with non-small cell lung cancer. <i>Oncologist</i> , <b>2013</b> , 18, 821-2	5.7	8
49	Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer. <i>BJU International</i> , <b>2013</b> , 111, 1269-80	5.6	38

48	Up-regulation of proliferative and migratory genes in regulatory T cells from patients with metastatic castration-resistant prostate cancer. <i>International Journal of Cancer</i> , <b>2013</b> , 133, 373-82	7.5	23
47	Soluble CD27-pool in humans may contribute to T cell activation and tumor immunity. <i>Journal of Immunology</i> , <b>2013</b> , 190, 6250-8	5.3	45
46	Prostate cancer: Intermediate efficacy end points to assess modern therapies. <i>Nature Reviews Urology</i> , <b>2013</b> , 10, 686-7	5.5	1
45	Novel immunotherapeutic agents for castration-resistant prostate cancer: update from clinical trials. <i>Clinical Investigation</i> , <b>2013</b> , 3, 651-663		
44	Therapeutic vaccines and immunotherapy in castration-resistant prostate cancer: current progress and clinical applications. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2013</b> ,	7.1	12
43	The role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literature. <i>European Urology</i> , <b>2012</b> , 61, 639-47	10.2	24
42	Clinical evaluation of TRICOM vector therapeutic cancer vaccines. <i>Seminars in Oncology</i> , <b>2012</b> , 39, 296-304	4.5	68
41	Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role. <i>Blood</i> , <b>2012</b> , 120, 3030-8	2.2	81
40	Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. <i>Lancet Oncology</i> , <b>2012</b> , 13, 501-8	21.7	299
39	Initial PSA oscillations precede prolonged stable disease in a patient treated with a therapeutic cancer vaccine. <i>Clinical Genitourinary Cancer</i> , <b>2012</b> , 10, 43-6	3.3	3
38	Therapeutic cancer vaccines in prostate cancer: the quest for intermediate markers of response. <i>Cancers</i> , <b>2012</b> , 4, 1229-46	6.6	3
37	Therapeutic cancer vaccines: the latest advancement in targeted therapy. <i>American Journal of Therapeutics</i> , <b>2012</b> , 19, e172-81	1	20
36	Combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity. <i>Oncolmmunology</i> , <b>2012</b> , 1, 1167-1168	7.2	17
35	The kinetics and reproducibility of 18F-sodium fluoride for oncology using current PET camera technology. <i>Journal of Nuclear Medicine</i> , <b>2012</b> , 53, 1175-84	8.9	57
34	Evolving role of chemotherapy in castration-resistant prostate cancer. <i>Clinical Practice (London, England)</i> , <b>2012</b> , 9, 301-313	3	
33	Strategies for optimizing the clinical impact of immunotherapeutic agents such as sipuleucel-T in prostate cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2012</b> , 10, 1505-12	7.3	11
32	Phase II trial of bevacizumab and lenalidomide with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 207-207	2.2	5
31	A pilot study on the clinical value of 18F-sodium fluoride PET/CT in advanced prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 10589-10589	2.2	0

30	A method for assessing tumor response to therapy and more precisely guiding treatment decisions so as to improve survival.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, e13122-e13122	2.2	
29	Immunotherapy in prostate cancer: emerging strategies against a formidable foe. <i>Vaccine</i> , <b>2011</b> , 29, 6485-97	4.1	16
28	Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination. <i>Cancer Immunology, Immunotherapy</i> , <b>2011</b> , 60, 197-206	7.4	47
27	Therapeutic cancer vaccine fulfills the promise of immunotherapy in prostate cancer. <i>Immunotherapy</i> , <b>2011</b> , 3, 27-31	3.8	9
26	Sipuleucel-T: harbinger of a new age of therapeutics for prostate cancer. <i>Expert Review of Vaccines</i> , <b>2011</b> , 10, 141-50	5.2	19
25	A pilot safety trial investigating a vector-based vaccine targeting carcinoembryonic antigen in combination with radiotherapy in patients with gastrointestinal malignancies metastatic to the liver. <i>Expert Opinion on Biological Therapy</i> , <b>2011</b> , 11, 1409-18	5.4	20
24	A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 7164-73	12.9	95
23	Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 907-17	12.9	188
22	Overcoming chemotherapy resistance in prostate cancer. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 3892-902	12.9	53
21	From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer. <i>Expert Review of Vaccines</i> , <b>2011</b> , 10, 743-53	5.2	15
20	Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 2070-6	2.2	126
19	Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression. <i>Oncologist</i> , <b>2010</b> , 15, 969-75	5.7	116
18	Therapeutic vaccines in metastatic castration-resistant prostate cancer: principles in clinical trial design. <i>Expert Opinion on Biological Therapy</i> , <b>2010</b> , 10, 19-28	5.4	26
17	Modern immunotherapy for the treatment of prostate cancer. <i>Drug Discovery Today: Therapeutic Strategies</i> , <b>2010</b> , 7, 37-42		0
16	The current and emerging role of immunotherapy in prostate cancer. <i>Clinical Genitourinary Cancer</i> , <b>2010</b> , 8, 10-6	3.3	9
15	Treatment of castration-resistant prostate cancer: updates on therapeutics targeting the androgen receptor signaling pathway. <i>American Journal of Therapeutics</i> , <b>2010</b> , 17, 176-81	1	6
14	Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. <i>Cancer Immunology, Immunotherapy</i> , <b>2010</b> , 59, 663-74	7.4	249
13	Vaccines as monotherapy and in combination therapy for prostate cancer. <i>Clinical and Translational Science</i> , <b>2010</b> , 3, 116-22	4.9	9

12 Cancer Immunology, Immunotherapeutics, and Vaccine Approaches **2010**, 305-319

11	Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. <i>Expert Opinion on Investigational Drugs</i> , <b>2009</b> , 18, 1001-11	5.9	161
10	Angiogenesis inhibition in the treatment of prostate cancer. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , <b>2009</b> , 9, 1070-8	2.2	6
9	Cancer vaccines: current directions and perspectives in prostate cancer. <i>Current Opinion in Molecular Therapeutics</i> , <b>2009</b> , 11, 31-6		5
8	Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 4526-31	12.9	121
7	Significant prostate-specific antigen (PSA) response to low-dose ketoconazole in a patient with non-metastatic androgen-independent prostate cancer (AIPC) and a review of the literature. <i>American Journal of Therapeutics</i> , <b>2007</b> , 14, 310-3	1	3
6	Combining Vaccines with Conventional Therapies for Cancer. <i>Update on Cancer Therapeutics</i> , <b>2007</b> , 2, 33-39		15
5	Enhancing efficacy of therapeutic vaccinations by combination with other modalities. <i>Vaccine</i> , <b>2007</b> , 25 Suppl 2, B89-96	4.1	58
4	PANVAC-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma. <i>Expert Opinion on Biological Therapy</i> , <b>2007</b> , 7, 543-54	5.4	60
3	Preclinical and clinical studies of recombinant poxvirus vaccines for carcinoma therapy. <i>Critical Reviews in Immunology</i> , <b>2007</b> , 27, 451-62	1.8	39
2	PSA-based vaccines for the treatment of prostate cancer. <i>Expert Review of Vaccines</i> , <b>2006</b> , 5, 199-209	5.2	22
1	Abiraterone. Cougar Biotechnology. <i>IDrugs: the Investigational Drugs Journal</i> , <b>2006</b> , 9, 49-55		5